HIV Infections Clinical Trials in Atlanta, Georgia

6 studies are recruiting for hiv infections in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

   The goal of this observational study is to generate real-life information on the use of lenacapavir (LEN, YEZTUGO®, (YTG)) for pre-exposure prophylaxis (PrEP) across diverse clinical settings in the United States. The study will characterize how PrEP is initiated, used, and discontinued in routine …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Faebris Medical & Community Education, Atlanta, Georgia

   Locations

   38 in total

   Run by

   Gilead Sciences

   See if you can join NCT07473778 on ClinicalTrials.gov

2. Screen2Prevent (S2P)

   Screen2Prevent is a study intended to improve HIV prevention and detection through implementation and evaluation of three different broad-scale HIV screening approaches a) targeted, b) universally offered opt-in, and c) universally offered opt-out in Emergency Departments (EDs) by leveraging digita…

   Stage

   Not phased

   Ages

   14 to 24

   Site

   Emory Atlanta Adolescent Consortium, Atlanta, Georgia

   Locations

   5 in total

   Run by

   Westat

   See if you can join NCT07728123 on ClinicalTrials.gov

3. Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

   The goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) versus (CAB) and rilpivirine (RPV) injections given every 8 weeks in adults with HIV-1 whose virus is well controlled on daily oral treatment…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Atlanta ID Group, PC, Atlanta, Georgia

   Locations

   19 in total

   Run by

   Gilead Sciences

   See if you can join NCT07682961 on ClinicalTrials.gov

4. A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

   This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection. The study is comparing two different doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide (FTC…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   GSK Investigational Site, Atlanta, Georgia

   Locations

   123 in total

   Run by

   ViiV Healthcare

   See if you can join NCT07202546 on ClinicalTrials.gov

5. HIV Treatment Adherence Dose Determination Trial

   The proposed research will conduct the first dose-determination trial to find the optimal number of behavioral counseling sessions (dose) needed to achieve and sustain optimal HIV treatment adherence. The results of this study will determine how much intervention is needed for whom and at what cost…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Connecticut Field Site, Atlanta, Georgia

   Locations

   2 in total

   Run by

   University of Connecticut

   See if you can join NCT04577313 on ClinicalTrials.gov

6. Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

   The purpose of this study is to provide data on the pharmacokinetic (PK), safety, tolerability, efficacy and acceptability of this fixed dose combination (FDC) single tablet 2-drug regimen for virologically suppressed (HIV-1 RNA [Ribonucleic Acid] < 50 [cells per milliliter] c/mL) children 6 to les…

   Stage

   Phase 1

   Ages

   6 to 12

   Site

   GSK Investigational Site, Atlanta, Georgia

   Locations

   8 in total

   Run by

   ViiV Healthcare

   See if you can join NCT05674656 on ClinicalTrials.gov